FDA Approves Opdivo for Hard-to-Treat Hodgkin Lymphoma

By Hope Cristol Patients with hard-to-treat Hodgkin lymphoma now have a new treatment option. The U.S. Food and Drug Administration granted accelerated approval to Opdivo (nivolumab) for classic Hodgkin lymphoma that has returned or progressed after a specific type of stem cell transplant and post-transplant medicine. Hodgkin lymphoma is a cancer of the lymph system, which is part of the immune system. There are two main types of this disease, but “classic” Hodgkin lymphoma accounts for about 95% of all cases in developed countries. The American Cancer Society estimates about 8,500 new cases of Hodgkin lymphoma will be diagnosed in 2016, with a 5-year survival rate ranging from 90% for stage I to 65% for stage IV. When Hodgkin lymphoma comes back after treatment (relapsed disease) or doesn’t go away after treatment (refractory disease), the next step is often an autologous stem cell transplant. This treatment uses high doses of chemotherapy, followed by reinfusing a patients’ own blood and marrow stem cells back into the body. The anticancer drug Adcetris (brentuximab vedotin) may be given to patients post-transplant. Opdivo, an immunotherapy drug, can now be used for Hodgkin lymphoma if these treatments don’t work. In clinical trials that formed the basis of the new approval, 95 patients with relapsed or refractory disease were treated with Opdivo. It was found to shrink tumors in 65% of patients: 58% achieved partial remission and 7% achie...
Source: American Cancer Society :: News and Features - Category: Cancer & Oncology Tags: Hodgkin Disease Source Type: news

Related Links:

In this study, MHC-1 and PDL-1 score in primary and metastatic tumor cells was evaluated in 43 gastric cancer patients with lymph node metastasis. According to our results, the primary tumor PDL-1 score was correlated with the number of metastatic lymph nodes (r = 0.258; p = 0.024) and primary tumor size (r = 0.341; p = 0.045). A similar correlation was found between the primary tumor PDL-1 score and the metastatic tumor PDL-1 score (r = 0.213; p = 0.015). In our study, MHC-1 was found to be higher in primary tumors than metastatic tumors, although not statistically significant (p = 0.054). The results of our study showed ...
Source: Gastroenterology Research and Practice - Category: Gastroenterology Tags: Gastroenterol Res Pract Source Type: research
Authors: McCarthy AJ, O'Reilly SM, Shanley J, Geraghty R, Ryan EJ, Cullen G, Sheahan K Abstract Background: As the malignant potential of sessile serrated lesions/polyps (SSL/Ps) and traditional serrated adenomas (TSAs) has been clearly demonstrated, it is important that serrated polyps are identified and correctly classified histologically. Aim: Our aim was to characterize the clinicopathological features of a series of SSL/Ps &TSAs, to assess the accuracy of the pathological diagnosis, the incidence, and the rate of dysplasia in SSL/Ps &TSAs. Methods: We identified all colorectal serrated polyps b...
Source: Gastroenterology Research and Practice - Category: Gastroenterology Tags: Gastroenterol Res Pract Source Type: research
CONCLUSION: The described tunneling flap approach allows a hermetic soft tissue closure, characterized by a reduction of dehiscence and a secure bone graft healing. The combination of thin autogenous bone blocks and bone particles according to the SBB technique allows an acceleration of transplant revascularization, and thus, of graft regeneration, allowing a shortening of the patient treatment time as well as long-term three-dimensional volumetric bone stability. PMID: 30883623 [PubMed - in process]
Source: International Journal of Oral and Maxillofacial Implants - Category: ENT & OMF Tags: Int J Oral Maxillofac Implants Source Type: research
Authors: Sartori EM, das Neves AM, Magro-Filho O, Mendonça DBS, Krebsbach PH, Cooper LF, Mendonça G Abstract Regulation of cellular function is key to bone formation at endosseous implant surfaces. Osseointegration was "discovered" prior to the discovery of genetic regulation of osteoinduction or characterization of mesenchymal stem cells. Understanding osseointegration in cellular and molecular terms has benefited from genome-wide characterization of this healing process at endosseous implants in vivo. These in vivo studies also demonstrate a role for osteoprogenitor cells and cells involve...
Source: International Journal of Oral and Maxillofacial Implants - Category: ENT & OMF Tags: Int J Oral Maxillofac Implants Source Type: research
Authors: Nagano M, Ayaki T, Koita N, Kitano T, Nishikori M, Goda N, Minamiguchi S, Ikeda A, Takaori-Kondo A, Takahashi R Abstract Primary central nervous system lymphoma (PCNSL) and chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS) can share clinical features and may be indistinguishable, even after brain biopsy. We encountered a case of Epstein-Barr virus-positive (EBV+) PCNSL recurrence in a patient with clinical features of CLIPPERS, and repeat brain biopsy was required to reach the correct diagnosis. Four years after the initial diagnosis and treatment of P...
Source: Internal Medicine - Category: Internal Medicine Tags: Intern Med Source Type: research
Publication date: Available online 18 March 2019Source: Molecular Aspects of MedicineAuthor(s): Laura Valle, Richarda M. de Voer, Yael Goldberg, Wenche Sjursen, Asta Försti, Clara Ruiz-Ponte, Trinidad Caldés, Pilar Garré, Maren F. Olsen, Margareta Nordling, Sergi Castellvi-Bel, Kari HemminkiAbstractThe present article summarizes recent developments in the characterization of genetic predisposition to colorectal cancer (CRC). The main themes covered include new hereditary CRC and polyposis syndromes, non-CRC hereditary cancer genes found mutated in CRC patients, strategies used to identify novel causal ge...
Source: Molecular Aspects of Medicine - Category: Molecular Biology Source Type: research
Publication date: March 2019Source: Biomolecular Detection and Quantification, Volume 17Author(s): Abel Jacobus Bronkhorst, Vida Ungerer, Stefan HoldenriederAbstractAn increasing number of studies demonstrate the potential use of cell-free DNA (cfDNA) as a surrogate marker for multiple indications in cancer, including diagnosis, prognosis, and monitoring. However, harnessing the full potential of cfDNA requires (i) the optimization and standardization of preanalytical steps, (ii) refinement of current analysis strategies, and, perhaps most importantly, (iii) significant improvements in our understanding of its origin, phys...
Source: Biomolecular Detection and Quantification - Category: Molecular Biology Source Type: research
Publication date: Available online 18 March 2019Source: Redox BiologyAuthor(s): Shen-Fei Wang, Xin Liu, Mo-Yu Ding, Shuangcheng Ma, Jing Zhao, Ying Wang, Shaoping LiAbstractReducing agents are crucial for the management of maladaptive inflammation-induced macrophage death and hematopoietic toxicity of chemotherapy. 2-O-β-d-glucopyranosyl-l-ascorbic acid (AA-2βG), a unique AA (or vitamin C) derivative identified in Lycium barbarum, exhibited enhanced free radical scavenging activity compared with AA and its synthetic derivative AA-2αG. AA-2βG protected hydrogen peroxide-induced cell death in murine macr...
Source: Redox Biology - Category: Biology Source Type: research
ConclusionLong non-coding RNA MALAT1 sponged miR-195 to regulate proliferation, apoptosis and migration and immune escape abilities of DLBCL by regulation of PD-L1.
Source: Life Sciences - Category: Biology Source Type: research
Authors: Kim MS, Lee CW, Kim JH, Lee JC, An WG Abstract Rhus verniciflua Stokes has long been used as a food supplement and traditional herbal medicine for various ailments in East Asia. We evaluated the anticancer effects of Rhus verniciflua Stokes extract (RVSE) on MCF-7 cells by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, flow cytometry, annexin V/7-AAD staining, and western blotting. In addition, the gallic acid content of RVSE was assayed using high-performance liquid chromatography. RVSE inhibited the growth of MCF-7 cells in a dose-dependent manner by inducing apoptosis in the sub-G1 ...
Source: Evidence-based Complementary and Alternative Medicine - Category: Complementary Medicine Tags: Evid Based Complement Alternat Med Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Food and Drug Administration (FDA) | Hodgkin's Disease | Immunotherapy | Kidney Cancer | Kidney Transplant | Kidney Transplantation | Lung Cancer | Lung Transplant | Lymphoma | Melanoma | Non-Small Cell Lung Cancer | Respiratory Medicine | Skin Cancer | Stem Cell Therapy | Stem Cells | Study | Transplant Surgery | Transplants | Urology & Nephrology